STOCKSCOUTER
StockScouter Premium
StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance
Learn more or Get it now! Stockscouter Portfolio performance
CYCC CYCLACEL PHARMACEUTICALS INCORPORATED StockScouter® Report
5
StockScouter® Score
CYCLACEL PHARMACEUTICALS INCORPORATED, a micro cap growth company in the healthcare sector, is expected to perform in line with the market over the next six months with higher than average risk
10 is the best possible rating. Learn more.
Summary
Positives
- The enterprise value-to-sales ratio is much lower than the average for comparably-sized companies in the StockScouter universe. Very Positive
- Earnings growth in the past year is holding steady compared to earnings growth in the past three years. Neutral
Concerns
- The multi-period measure of relative price change and consistency is well below average. Negative
- Moving average analysis for CYCC suggests weak price movement over the medium term. Negative
Short-term Outlook
Over the next 1-2 months, StockScouter forecasts that micro cap stocks will be out of favor, growth stocks will be out of favor, and healthcare stocks will be out of favor.
Expected Risk/Return
Core Model Grades
D
N/A
A
F